Björkholm Carl, Monteggia Lisa M
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Neuropharmacology. 2016 Mar;102:72-9. doi: 10.1016/j.neuropharm.2015.10.034. Epub 2015 Nov 11.
How do antidepressants elicit an antidepressant response? Here, we review accumulating evidence that the neurotrophin brain-derived neurotrophic factor (BDNF) serves as a transducer, acting as the link between the antidepressant drug and the neuroplastic changes that result in the improvement of the depressive symptoms. Over the last decade several studies have consistently highlighted BDNF as a key player in antidepressant action. An increase in hippocampal and cortical expression of BDNF mRNA parallels the antidepressant-like response of conventional antidepressants such as SSRIs. Subsequent studies showed that a single bilateral infusion of BDNF into the ventricles or directly into the hippocampus is sufficient to induce a relatively rapid and sustained antidepressant-like effect. Importantly, the antidepressant-like response to conventional antidepressants is attenuated in mice where the BDNF signaling has been disrupted by genetic manipulations. Low dose ketamine, which has been found to induce a rapid antidepressant effect in patients with treatment-resistant depression, is also dependent on increased BDNF signaling. Ketamine transiently increases BDNF translation in hippocampus, leading to enhanced synaptic plasticity and synaptic strength. Ketamine has been shown to increase BDNF translation by blocking NMDA receptor activity at rest, thereby inhibiting calcium influx and subsequently halting eukaryotic elongation factor 2 (eEF2) kinase leading to a desuppression of protein translation, including BDNF translation. The antidepressant-like response of ketamine is abolished in BDNF and TrkB conditional knockout mice, eEF2 kinase knockout mice, in mice carrying the BDNF met/met allele, and by intra-cortical infusions of BDNF-neutralizing antibodies. In summary, current data suggests that conventional antidepressants and ketamine mediate their antidepressant-like effects by increasing BDNF in forebrain regions, in particular the hippocampus, making BDNF an essential determinant of antidepressant efficacy.
抗抑郁药是如何引发抗抑郁反应的?在此,我们回顾了越来越多的证据,即神经营养因子脑源性神经营养因子(BDNF)作为一种转换器,充当抗抑郁药物与导致抑郁症状改善的神经可塑性变化之间的联系。在过去十年中,多项研究一致强调BDNF是抗抑郁作用的关键因素。BDNF mRNA在海马体和皮质中的表达增加与传统抗抑郁药(如选择性5-羟色胺再摄取抑制剂(SSRI))的抗抑郁样反应相似。随后的研究表明,将BDNF单次双侧注入脑室或直接注入海马体足以诱导相对快速且持续的抗抑郁样效果。重要的是,在通过基因操作破坏BDNF信号传导的小鼠中,对传统抗抑郁药的抗抑郁样反应减弱。低剂量氯胺酮已被发现可在难治性抑郁症患者中诱导快速抗抑郁作用,它也依赖于BDNF信号传导的增加。氯胺酮可短暂增加海马体中BDNF的翻译,从而增强突触可塑性和突触强度。氯胺酮已被证明通过在静息时阻断N-甲基-D-天冬氨酸(NMDA)受体活性来增加BDNF翻译,从而抑制钙内流,随后使真核生物延伸因子2(eEF2)激酶失活,导致包括BDNF翻译在内的蛋白质翻译去抑制。在BDNF和酪氨酸激酶受体B(TrkB)条件性敲除小鼠、eEF2激酶敲除小鼠、携带BDNF met/met等位基因的小鼠以及通过皮质内注入BDNF中和抗体的小鼠中,氯胺酮的抗抑郁样反应被消除。总之,目前的数据表明,传统抗抑郁药和氯胺酮通过增加前脑区域(特别是海马体)中的BDNF来介导其抗抑郁样作用,这使得BDNF成为抗抑郁疗效的重要决定因素。